Scotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by Scotiabank from $44.00 to $41.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the stock. Scotiabank’s price target points to a potential upside of 293.29% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Guggenheim downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th. Wedbush reiterated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. HC Wainwright decreased their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Finally, BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $70.22.

Keros Therapeutics Stock Up 0.0 %

Shares of Keros Therapeutics stock traded up $0.01 on Thursday, hitting $10.43. 2,203,246 shares of the company’s stock traded hands, compared to its average volume of 2,462,024. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The stock has a market cap of $422.32 million, a P/E ratio of -2.00 and a beta of 1.43. The firm’s 50-day moving average is $39.77 and its 200 day moving average is $47.88.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.33) EPS. Equities research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Trading of Keros Therapeutics

Large investors have recently modified their holdings of the company. Point72 Asset Management L.P. boosted its stake in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. Alkeon Capital Management LLC raised its holdings in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after buying an additional 223,155 shares during the period. Assenagon Asset Management S.A. grew its holdings in Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares in the last quarter. Finally, FMR LLC increased its position in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after acquiring an additional 179,374 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.